New licence provides CHUM access to the ERS CRISPR/Cas9 patent portfolio. DUBLIN and MONTREAL, Oct. 26, 2023 /PRNewswire/ — ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with the CHUM Research Centre (‘(CRCHUM),’). This is a non-exclusive licensing agreement granting the CRCHUM research rights to the ERS CRISPR/Cas9 patent portfolio..Read Full Article
Schedule time with ERS
‘If you’re using or plan to use CRISPR/Cas9
technology, you need a License
from ERS Genomics.’
Connect with us @ Bio Boston in June.
Getting a license is easy, fast & flexible.
Jon Kratochvil, Vice President, ERS Genonics.